Active U.S. Investigational New Drug (IND) status extends Phase 2b clinical study in moderate to severe Ulcerative Colitis (UC) clinical trial to U.S. patients ABX464 Phase 2b UC trial is already ongoing in 15 European countries and Canada Enrollment of first U.S....
Mayzent® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe1 Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did...
LONDON, Jan 20, 2020 (GLOBE NEWSWIRE via COMTEX) — LONDON, Jan. 20, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (aim/nasdaq:HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the...
Fasenra being evaluated in eight eosinophil-driven diseases beyond severe asthma AstraZeneca today announced three new trials for Fasenra (benralizumab) in skin diseases, adding to five trials already underway for the medicine in eosinophil-driven diseases (EDDs)...
Surge of Research Organizations Investing in Florence Shows New Wave of Site Leadership in Streamlining Study Operations ATLANTA – January 16, 2020 – (Newswire.com) Florence, an Atlanta-based clinical trial software company, today announces that it doubled...
Email
Text